Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$306.95
+0.4%
$301.08
$253.30
$346.85
$164.90B0.532.69 million shs1.77 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$820.30
-0.2%
$844.31
$711.40
$972.53
$777.78B0.343.30 million shs2.12 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$69.36
-1.1%
$82.33
$67.80
$148.15
$311.23B0.425.54 million shs5.85 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.20
+0.8%
$26.06
$24.48
$31.54
$142.93B0.6138.88 million shs32.32 million shs
WW International, Inc. stock logo
WW
WW International
$0.50
-7.3%
$0.76
$0.38
$2.35
$40.03M1.834.52 million shs1.15 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%-2.88%-0.36%+18.38%+7.96%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-2.28%-10.88%+6.00%+5.44%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%-9.78%-23.51%-19.10%-45.99%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%-3.83%-4.65%-4.61%-9.19%
WW International, Inc. stock logo
WW
WW International
0.00%-10.79%-21.94%-60.66%-72.99%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.4238 of 5 stars
2.24.03.33.93.62.50.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8006 of 5 stars
2.45.03.34.03.42.51.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.8111 of 5 stars
4.45.02.50.01.90.04.4
Pfizer Inc. stock logo
PFE
Pfizer
4.9866 of 5 stars
3.33.04.24.23.33.33.1
WW International, Inc. stock logo
WW
WW International
2.0093 of 5 stars
3.13.00.00.02.91.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.48
Hold$314.042.31% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7223.09% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.80
Moderate Buy$145.25109.43% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.63
Moderate Buy$31.9226.67% Upside
WW International, Inc. stock logo
WW
WW International
2.20
Hold$3.00500.48% Upside

Current Analyst Ratings Breakdown

Latest WW, AMGN, LLY, NVO, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/13/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/5/2025
Amgen Inc. stock logo
AMGN
Amgen
Johnson Rice
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$294.00
3/5/2025
Amgen Inc. stock logo
AMGN
Amgen
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$275.00 ➝ $294.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
3/3/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/12/2025
Amgen Inc. stock logo
AMGN
Amgen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/12/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight
(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$33.42B4.93$30.76 per share9.98$10.93 per share28.08
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.27$13.37 per share61.34$15.05 per share54.50
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$290.40B1.07$3.22 per share21.57$4.64 per share14.95
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.25$3.95 per share6.38$15.81 per share1.59
WW International, Inc. stock logo
WW
WW International
$785.92M0.05$0.42 per share1.18($9.62) per share-0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$4.09B$7.5540.6614.352.6312.24%176.32%11.71%5/1/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.0526.361.4023.51%85.24%16.19%5/1/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.2921.0814.880.9034.81%84.68%26.29%5/1/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.878.320.6412.62%19.47%8.09%4/29/2025 (Estimated)
WW International, Inc. stock logo
WW
WW International
-$112.25M-$4.37N/AN/AN/A-56.84%N/A-0.32%5/1/2025 (Estimated)

Latest WW, AMGN, LLY, NVO, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/27/2025Q4 2024
WW International, Inc. stock logo
WW
WW International
$0.01$0.32+$0.31$0.31$173.23 million$184.41 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
2/5/2025Q4 2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.88$0.91+$0.03$0.91N/AN/A
2/4/2025Q4 2024
Amgen Inc. stock logo
AMGN
Amgen
$5.04$5.31+$0.27$1.16$8.87 billionN/A
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.523.10%+8.53%126.09%14 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.572.26%+25.26%47.72%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.83%+2.50%121.99%16 Years
WW International, Inc. stock logo
WW
WW International
N/AN/AN/AN/AN/A

Latest WW, AMGN, LLY, NVO, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/4/2025
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.383.05%5/16/20255/16/20256/6/2025
2/5/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.78741.2%3/31/20253/31/20254/8/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
9.62
1.26
0.95
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
WW International, Inc. stock logo
WW
WW International
N/A
0.53
0.53

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
WW International, Inc. stock logo
WW
WW International
86.18%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.69%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
WW International, Inc. stock logo
WW
WW International
8.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
28,000537.21 million533.50 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable
WW International, Inc. stock logo
WW
WW International
4,85080.13 million73.38 millionOptionable

Recent News About These Companies

Q4 2024 WW International Inc Earnings Call
WW International (WW) Gets a Hold from Craig-Hallum

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amgen stock logo

Amgen NASDAQ:AMGN

$306.95 +1.18 (+0.39%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$304.02 -2.94 (-0.96%)
As of 03/28/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$820.30 -1.37 (-0.17%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$815.45 -4.85 (-0.59%)
As of 03/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$69.36 -0.81 (-1.15%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$69.36 +0.01 (+0.01%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$25.20 +0.19 (+0.76%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$25.14 -0.07 (-0.26%)
As of 03/28/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

WW International stock logo

WW International NASDAQ:WW

$0.50 -0.04 (-7.31%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$0.50 +0.00 (+0.88%)
As of 03/28/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

WW International, Inc. provides weight management products and services worldwide. It offers a range of nutritional, activity, behavioral, and lifestyle tools and approaches products and services. The company also provides various digital subscription products to wellness and weight management business, which provide interactive and personalized resources that allow users to follow its weight management program through its app and web-based platform; and allows members to inspire and support each other by sharing their experiences with other people on weight health journeys. In addition, it licenses its trademarks and other intellectual property in food, beverages, and other relevant consumer products and services, as well as provides publishing services. The company was formerly known as Weight Watchers International, Inc. and changed its name to WW International, Inc. in September 2019. WW International, Inc. was founded in 1961 and is headquartered in New York, New York.